| scholarly article | Q13442814 |
| P6179 | Dimensions Publication ID | 1001742245 |
| P356 | DOI | 10.1038/SJ.ONC.1208954 |
| P698 | PubMed publication ID | 16103877 |
| P5875 | ResearchGate publication ID | 7656535 |
| P2093 | author name string | Ali R Jazirehi | |
| Benjamin Bonavida | |||
| Hermes Garban | |||
| Sara Huerta-Yepez | |||
| Mario I Vega | |||
| P2860 | cites work | NF-kappaB-mediated up-regulation of Bcl-x and Bfl-1/A1 is required for CD40 survival signaling in B lymphocytes | Q24685661 |
| Association of 75/80-kDa phosphoproteins and the tyrosine kinases Lyn, Fyn, and Lck with the B cell molecule CD20. Evidence against involvement of the cytoplasmic regions of CD20 | Q28288440 | ||
| Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma | Q28297805 | ||
| Discovery of a novel, potent, and Src family-selective tyrosine kinase inhibitor. Study of Lck- and FynT-dependent T cell activation | Q29617586 | ||
| An anti-C3b(i) mAb enhances complement activation, C3b(i) deposition, and killing of CD20+ cells by rituximab | Q30310160 | ||
| Function and regulation of the CD95 (APO-1/Fas) ligand in the immune system | Q35561571 | ||
| The CD95 type I/type II model | Q35561587 | ||
| Cellular and molecular signal transduction pathways modulated by rituximab (rituxan, anti-CD20 mAb) in non-Hodgkin's lymphoma: implications in chemosensitization and therapeutic intervention | Q36079223 | ||
| The binding affinity of human IgG for its high affinity Fc receptor is determined by multiple amino acids in the CH2 domain and is modulated by the hinge region | Q36361038 | ||
| Human T-cell leukemia virus type I tax protein induces the expression of anti-apoptotic gene Bcl-xL in human T-cells through nuclear factor-kappaB and c-AMP responsive element binding protein pathways | Q39269100 | ||
| Inhibition of the Raf-MEK1/2-ERK1/2 signaling pathway, Bcl-xL down-regulation, and chemosensitization of non-Hodgkin's lymphoma B cells by Rituximab. | Q40507932 | ||
| Nitric oxide inhibits the transcription repressor Yin-Yang 1 binding activity at the silencer region of the Fas promoter: a pivotal role for nitric oxide in the up-regulation of Fas gene expression in human tumor cells | Q43648164 | ||
| The mechanism of tumor cell clearance by rituximab in vivo in patients with B-cell chronic lymphocytic leukemia: evidence of caspase activation and apoptosis induction | Q43863953 | ||
| Constitutive activation of extracellular signal-regulated kinase and p38 mitogen-activated protein kinase in B-cell lymphoproliferative disorders | Q44458721 | ||
| Mitoxantrone–cyclophosphamide–rituximab: an effective and safe combination for indolent NHL | Q44632533 | ||
| Nitric oxide sensitizes prostate carcinoma cell lines to TRAIL-mediated apoptosis via inactivation of NF-kappa B and inhibition of Bcl-xl expression. | Q46074399 | ||
| Rituximab inhibits p38 MAPK activity in 2F7 B NHL and decreases IL-10 transcription: pivotal role of p38 MAPK in drug resistance. | Q46184588 | ||
| Antibody specificity controls in vivo effector mechanisms of anti-CD20 reagents | Q57271792 | ||
| Novel inhibitors of cytokine-induced IkappaBalpha phosphorylation and endothelial cell adhesion molecule expression show anti-inflammatory effects in vivo | Q73596145 | ||
| Signaling events involved in anti-CD20-induced apoptosis of malignant human B cells | Q73638542 | ||
| CD20 levels determine the in vitro susceptibility to rituximab and complement of B-cell chronic lymphocytic leukemia: further regulation by CD55 and CD59 | Q77220551 | ||
| Lack of constitutive activation of MAP kinase pathway in human acute myeloid leukemia cells with N-Ras mutation | Q77360749 | ||
| Specific activation of the p38 mitogen-activated protein kinase signaling pathway and induction of neurite outgrowth in PC12 cells by bone morphogenetic protein-2 | Q78208149 | ||
| P433 | issue | 55 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | rituximab | Q412323 |
| P304 | page(s) | 8114-8127 | |
| P577 | publication date | 2005-12-01 | |
| P1433 | published in | Oncogene | Q1568657 |
| P1476 | title | Rituximab (chimeric anti-CD20) sensitizes B-NHL cell lines to Fas-induced apoptosis | |
| P478 | volume | 24 |
| Q33374113 | Autoimmune thrombopenia associated with hepatitis B reactivation (reverse seroconversion) after autologous hematopoietic stem cell transplantation |
| Q47773932 | CRHR2/Ucn2 signaling is a novel regulator of miR-7/YY1/Fas circuitry contributing to reversal of colorectal cancer cell resistance to Fas-mediated apoptosis |
| Q35919697 | Combinatorial chemotherapeutic efficacy in non-Hodgkin lymphoma can be predicted by a signaling model of CD20 pharmacodynamics |
| Q38309488 | Distinct promoters mediate constitutive and inducible Bcl-XL expression in malignant lymphocytes. |
| Q37893414 | Emerging antibody combinations in oncology |
| Q34117122 | Epstein-Barr virus in bone marrow of rheumatoid arthritis patients predicts response to rituximab treatment. |
| Q34564852 | Essential dosage-dependent functions of the transcription factor yin yang 1 in late embryonic development and cell cycle progression |
| Q37693873 | Galiximab (anti-CD80)-induced growth inhibition and prolongation of survival in vivo of B-NHL tumor xenografts and potentiation by the combination with fludarabine |
| Q39305171 | Inhibition of p38 MAPK activity in B-NHL Raji cells by treatment with engineered CD20-specific T cells |
| Q41787771 | Keynote lecture in the 13th Japanese Society of Immunotoxicology (JSIT 2006) : -Pathophysiological Development and Immunotoxicology: what we have found from research related to silica and silicate such as asbestos-. |
| Q55447366 | Knockdown of Yin Yang 1 enhances anticancer effects of cisplatin through protein phosphatase 2A-mediated T308 dephosphorylation of AKT. |
| Q40061736 | Lysophosphatidylcholine upregulates LOX-1, chemokine receptors, and activation-related transcription factors in human T-cell line Jurkat |
| Q37288826 | Mechanism of Fas signaling regulation by human herpesvirus 8 K1 oncoprotein |
| Q36157946 | Mechanisms of Yin Yang 1 in oncogenesis: the importance of indirect effects |
| Q34369841 | Multiple signaling pathways induced by hexavalent, monospecific, anti-CD20 and hexavalent, bispecific, anti-CD20/CD22 humanized antibodies correlate with enhanced toxicity to B-cell lymphomas and leukemias |
| Q38542034 | Natural killer (NK) cells and anti-tumor therapeutic mAb: unexplored interactions. |
| Q26782525 | Nitric oxide-mediated sensitization of resistant tumor cells to apoptosis by chemo-immunotherapeutics |
| Q58704356 | RKIP: A Key Regulator in Tumor Metastasis Initiation and Resistance to Apoptosis: Therapeutic Targeting and Impact |
| Q33623823 | Receptor-interacting protein shuttles between cell death and survival signaling pathways |
| Q36832106 | Rituximab-induced inhibition of antiapoptotic cell survival pathways: implications in chemo/immunoresistance, rituximab unresponsiveness, prognostic and novel therapeutic interventions |
| Q34124932 | Rituximab: a review of its use in chronic lymphocytic leukaemia, low-grade or follicular lymphoma and diffuse large B-cell lymphoma |
| Q83362579 | Rituximab: a review of its use in non-Hodgkin's lymphoma and chronic lymphocytic leukaemia |
| Q37875060 | Rituximab: as first-line maintenance therapy following rituximab-containing therapy for follicular lymphoma |
| Q28486745 | Silencing of human phosphatidylethanolamine-binding protein 4 enhances rituximab-induced death and chemosensitization in B-cell lymphoma |
| Q28272373 | Targeting NF-kappaB in Waldenstrom macroglobulinemia |
| Q38120535 | Targeting of the tumor necrosis factor receptor superfamily for cancer immunotherapy |
| Q37165666 | The Yin and Yang of YY1 in the nervous system |
| Q38880669 | The gold (III) porphyrin complex, gold-2a, suppresses WNT1 expression in breast cancer cells by enhancing the promoter association of YY1. |
| Q28385924 | The oncogenic role of Yin Yang 1 |
| Q36453798 | The peptide derived from the Ig-like domain of human herpesvirus 8 K1 protein induces death in hematological cancer cells. |
| Q36350378 | Transcription regulator Yin-yang 1: from silence to cancer |
| Q37672125 | Understanding and circumventing resistance to anticancer monoclonal antibodies. |
| Q34401328 | Using functional genomics to overcome therapeutic resistance in hematological malignancies. |
Search more.